Matthew Herper

A powerful story of how our nation’s leaders overcame the odds, saving the American people from the throes of a deadly pandemic. The prior record for vaccine development and distribution was approximately 4.5 years. Operation Warp Speed got the COVID-19 vaccine to the American people in less than 10 months. Operation Warp Speed did not happen by accident. It was the result of exceptional leadership, explicit strategy, and unprecedented teamwork. Author Paul Mango, the foremost leader of Operation Warp Speed and the former deputy chief of US Health and Human Services, chronicles the challenges and real dangers of developing the vaccine. From the beginning, two lead scientists, Dr. Moncef Slaoui and Dr. Debra Birx, fought head to head on which vaccines had the greatest probability of success. Tensions grew as the Army Materiel Command and the Center for Disease Control debated on whether public health agencies or the private sector would take over vaccine distribution. Mango details the largest hurdle for the Operation Warp Speed team: though Pfizer, the first distribution company to deliver the mRNA vaccine, sought aid from the Federal Government, they refused the government’s request to oversee safe manufacturing of the vaccine, eventually leading to a major scandal as Pfizer missed its contractual obligation to deliver 40 million doses by the end of 2020, the number of positive cases reaching a frightening peak all the while. In this harrowing, behind-the-scenes account of the most successful public-private partnership since World War II, we learn how the nation’s biggest leaders accomplished the impossible. Through sheer will and exceptional commitment, a small group of leaders fulfilled its mission, making the United States the only country in the world which could offer a vaccine to any citizen by April 2021, scarcely 14 months after the genetic identification of the virus.

Two iconic bands. An unforgettable life. One of the most dynamic groups of the ‘70s and ‘80s, Talking Heads, founded by drummer Chris Frantz, his girlfriend Tina Weymouth, and lead singer David Byrne, burst onto the music scene, playing at CBGBs, touring Europe with the Ramones, and creating hits like “Psycho Killer” and “Burning Down the House” that captured the post-baby boom generation’s intense, affectless style. In Remain in Love, Frantz writes about the beginnings of Talking Heads―their days as art students in Providence, moving to the sparse Chrystie Street loft Frantz, Weymouth, and Byrne shared where the music that defined an era was written. With never-before-seen photos and immersive vivid detail, Frantz describes life on tour, down to the meals eaten and the clothes worn―and reveals the mechanics of a long and complicated working relationship with a mercurial frontman. At the heart of Remain in Love is Frantz’s love for Weymouth: their once-in-a-lifetime connection as lovers, musicians, and bandmates, and how their creativity surged with the creation of their own band Tom Tom Club, bringing a fresh Afro-Caribbean beat to hits like “Genius of Love.” Studded with memorable places and names from the era―Grace Jones, Andy Warhol, Stephen Sprouse, Lou Reed, Brian Eno, and Debbie Harry among them―Remain in Love is a frank and open memoir of an emblematic life in music and in love.

LOS ANGELES TIMES AND PUBLISHERS WEEKLY BESTSELLER • The powerful memoir of a young doctor and former college athlete diagnosed with a rare disease who spearheaded the search for a cure—and became a champion for a new approach to medical research. “A wonderful and moving chronicle of a doctor’s relentless pursuit, this book serves both patients and physicians in demystifying the science that lies behind medicine.”—Siddhartha Mukherjee, New York Times bestselling author of The Emperor of All Maladies and The Gene David Fajgenbaum, a former Georgetown quarterback, was nicknamed the Beast in medical school, where he was also known for his unmatched mental stamina. But things changed dramatically when he began suffering from inexplicable fatigue. In a matter of weeks, his organs were failing and he was read his last rites. Doctors were baffled by his condition, which they had yet to even diagnose. Floating in and out of consciousness, Fajgenbaum prayed for a second chance, the equivalent of a dramatic play to second the game into overtime. Miraculously, Fajgenbaum survived—only to endure repeated near-death relapses from what would eventually be identified as a form of Castleman disease, an extremely deadly and rare condition that acts like a cross between cancer and an autoimmune disorder. When he relapsed while on the only drug in development and realized that the medical community was unlikely to make progress in time to save his life, Fajgenbaum turned his desperate hope for a cure into concrete action: Between hospitalizations he studied his own charts and tested his own blood samples, looking for clues that could unlock a new treatment. With the help of family, friends, and mentors, he also reached out to other Castleman disease patients and physicians, and eventually came up with an ambitious plan to crowdsource the most promising research questions and recruit world-class researchers to tackle them. Instead of waiting for the scientific stars to align, he would attempt to align them himself. More than five years later and now married to his college sweetheart, Fajgenbaum has seen his hard work pay off: A treatment  he identified has induced a tentative remission and his novel approach to collaborative scientific inquiry has become a blueprint for advancing rare disease research. His incredible story demonstrates the potency of hope, and what can happen when the forces of determination, love, family, faith, and serendipity collide. Praise for Chasing My Cure “A page-turning chronicle of living, nearly dying, and discovering what it really means to be invincible in hope.”—Angela Duckworth, #1 New York Times bestselling author of Grit “[A] remarkable memoir . . . Fajgenbaum writes lucidly and movingly . . . Fajgenbaum’s stirring account of his illness will inspire readers.”—Publishers Weekly